Metástasis tiroidea metacronica secundaria a carcinoma renal: A propósito de un caso

Rodríguez, Jorge García-Olaverri; Mateo, A; Arin, Igor Azurmendi; Grasa, Iban Olano; Ibarguren, Roberto Llarena; Peña, Carlos Pertusa

doi:10.4321/s0004-06142007000600015

Cited by 3 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our patient presented with left thyroid lobe metastases 8 months after nephrectomy that required hemithyroidectomy as treatment. The clinical presentation was similar to data reported in the literature, emphasizing the importance of raised suspicion of metastases in all patients with a history of RCC and thyroid volume increase [5]. …”

Section: Discussionsupporting

confidence: 80%

An Unusual Metastatic Renal Cell Carcinoma with Maintained Complete Response to Sunitinib Treatment

Chara

Rodriguez²,

Holgado³

et al. 2011

Case Rep Oncol

View full text Add to dashboard Cite

Recently, metastatic renal cell carcinoma (mRCC) treatment has changed dramatically with the onset of new therapies against molecular targets replacing immunotherapy as standard treatment. We report the case of a 49-year-old patient with a moderately differentiated renal clear cell carcinoma without extracapsular extension who underwent radical nephrectomy. Eight months after surgery, he developed a thyroid metastasis which was also treated surgically with a hemithyroidectomy. Seventy-five months after nephrectomy, the patient presented an upper gastrointestinal bleeding due to a duodenal metastasis that infiltrates the head of the pancreas. The treatment applied was surgery by duodenopancreatectomy, with positive surgical margins in the pathologic study. In addition to this, the extension study showed lung metastases requiring initiation of systemic treatment with sunitinib. The patient presented an excellent response to treatment, showing complete clinical and radiological response at 5 months of treatment (RECIST criteria) and a disease-free survival of 48 months until now, without evidence of toxicity. RCC has the potential to metastasize to almost any location, but thyroid and duodenal metastases in RCC are extremely rare. Moreover, this case also highlights the good responses that can be achieved in terms of disease-free survival, low toxicity and quality of life in this new era of therapies against molecular targets.

show abstract

Section: Discussionsupporting

confidence: 80%

An Unusual Metastatic Renal Cell Carcinoma with Maintained Complete Response to Sunitinib Treatment

Chara

Rodriguez²,

Holgado³

et al. 2011

Case Rep Oncol

View full text Add to dashboard Cite

show abstract

“…In 70% of cases the primary source of thyroid metastases is the RCC [ 8 , 18 ]. Most authors believe 1% to 5% of RCC metastases are localised in the thyroid gland [ 4 , 19 , 20 ]. Thyroid metastases are most commonly metachronic and appear earlier than in the pancreas [ 6 , 20 ].…”

mentioning

confidence: 99%

“…Most authors believe 1% to 5% of RCC metastases are localised in the thyroid gland [ 4 , 19 , 20 ]. Thyroid metastases are most commonly metachronic and appear earlier than in the pancreas [ 6 , 20 ]. Mean time from nephrectomy due to RCC to the diagnosis of thyroid metastasis is about 10 years [ 20 ], and the longest disease-free interval following radical nephrectomy was 24 years [ 21 ].…”

mentioning

confidence: 99%

“…Thyroid metastases are most commonly metachronic and appear earlier than in the pancreas [ 6 , 20 ]. Mean time from nephrectomy due to RCC to the diagnosis of thyroid metastasis is about 10 years [ 20 ], and the longest disease-free interval following radical nephrectomy was 24 years [ 21 ]. Renal cell carcinoma metastases to the thyroid are macroscopically similar to primary thyroid neoplasms [ 21 ].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Renal cell carcinoma metastases to the pancreas and the thyroid gland 19 years after the primary tumour

Wolf

Obołończyk

Sworczak

et al. 2015

View full text Add to dashboard Cite

Thyroid Metastases from Renal Cell Carcinoma: Review of the Literature

Sindoni

Rizzo

Tuccari

et al. 2010

The Scientific World JOURNAL

View full text Add to dashboard Cite

The thyroid gland is a rare site of clinically detectable tumor metastasis and kidneys are frequently the site of the parent malignancy. In the present review on thyroid metastases from renal cell carcinoma, cases were searched on PubMed by entering the strings: “renal carcinoma [or“hypernephroma”] AND thyroid metastasis/metastases”. Thus, we retrieved a total of 111 cases that were published between 1964 and 2007, a total that became 113 by adding two patients observed by us. The female to male ratio was 1.35:1. The primary renal cancer was almost always unilateral (90%) (with no significant side preference) and only rarely bilateral (9% in men, 4% in women), whereas bilaterality of thyroid metastases was relatively more frequent (28%). Thyroid metastasis from renal cancer was commonly single with a unique node that appears solid and hypoechoic at ultrasonography, approximately 9 years after nephrectomy. Concordance of lateralization was insignificantly greater for the right kidney/right thyroid lobe pattern (54%) than for the left kidney/left thyroid lobe pattern (40%), regardless of gender. Finally, survival was longer for women. Thyroid metastases, even if rare in the clinical practice, must be considered in the differential diagnosis of a thyroid nodule, particularly in patients who have a history of malignancies.

show abstract

Metástasis tiroidea metacronica secundaria a carcinoma renal: A propósito de un caso

Cited by 3 publications

References 7 publications

An Unusual Metastatic Renal Cell Carcinoma with Maintained Complete Response to Sunitinib Treatment

An Unusual Metastatic Renal Cell Carcinoma with Maintained Complete Response to Sunitinib Treatment

Renal cell carcinoma metastases to the pancreas and the thyroid gland 19 years after the primary tumour

Thyroid Metastases from Renal Cell Carcinoma: Review of the Literature

Contact Info

Product

Resources

About